Treatment

Treatment is determined by the type and stage of cancer, as well as by what treatments and services a patient chooses. The guidelines and other documents available here focus on topics related to the treatment of cancer in Ontario.

Multidisciplinary Cancer Conferences

Displaying Guidelines

30 articles

Alemtuzumab for the Treatment of T-cell Prolymphocytic Leukemia

Document Status: Archived
ID: 6-22

Jan 2007

Bevacizumab for Recurrent Glioblastoma Multiforme (GBM)

Document Status: Archived
ID: CED 19

Jul 2010

Bortezomib in Multiple Myeloma and Lymphoma

Document Status: Archived
ID: 6-18
Version: 2

Jun 2016

Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma

Document Status: Current
ID: GL 4-18
Version: N/A

Sep 2020

Dasatinib for the Treatment of Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia

Document Status: Archived
ID: 6-23 (CED)

Jan 2012

Dose-intensive Chemotherapy with Growth Factor or Autologous Bone Marrow/Stem Cell Transplant Support in Advanced or Metastatic Adult Soft Tissue Sarcoma

Document Status: Archived
ID: 11-5

Sep 2011

Ibritumomab Tiuxetan in Lymphoma

Document Status: Archived
ID: 6-17

Nov 2013

Imatinib Mesylate (Gleevec™) for the Treatment of Adult Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumours

Document Status: Archived
ID: 11-7
Version: 3

May 2015

Imatinib Mesylate in the Adjuvant Treatment of Gastrointestinal Stromal Tumours (GIST)

Document Status: Archived
ID: CED 17

Mar 2010

Iodine-131 Tositumomab in Lymphoma

Document Status: Archived
ID: 6-19

Jan 2007

Management of Cancer Medication-Related Infusion Reactions

Document Status: Current
Version: 1

Aug 2019

Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma

Document Status: Current
ID: GL 4-1
Version: 2

Jan 2021